Cadrenal Therapeutics Inc (CVKD) USD0.001

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development of tecarfarin, a new phase III-ready oral vitamin K antagonist anticoagulant to address unmet needs in anticoagulation therapy. Tecarfarin is a novel and reversible anticoagulant designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation. It is pursuing a product-in-a-pipeline approach with tecarfarin. Tecarfarin has orphan drug designation (ODD) for advanced heart failure patients with implanted mechanical circulatory support devices, including left ventricular assisted devices (LVADs). The Company also has ODD and fast-track status for tecarfarin in end-stage kidney disease and atrial fibrillation (ESKD+AFib). With tecarfarin, it is advancing a solution to address the unmet needs in anticoagulation therapy, aiming to reduce the clinical complexities of warfarin, a vitamin K antagonist.